

# Eiji Oki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7067837/publications.pdf>

Version: 2024-02-01

399  
papers

8,664  
citations

46918

47  
h-index

82410

72  
g-index

412  
all docs

412  
docs citations

412  
times ranked

12565  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	15.2	209
2	Deregulation of the Akt Pathway in Human Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 27-36.	0.8	199
3	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018, 24, 968-977.	15.2	196
4	Activation of PI3K/Akt signaling and hormone resistance in breast cancer. <i>Breast Cancer</i> , 2006, 13, 137-144.	1.3	182
5	Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. <i>International Journal of Cancer</i> , 2005, 117, 376-380.	2.3	170
6	Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. <i>International Journal of Cancer</i> , 2006, 118, 284-289.	2.3	163
7	Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rho GTPase 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. <i>Gastroenterology</i> , 2017, 153, 191-204.e16.	0.6	158
8	Advances in esophageal cancer surgery in Japan: An analysis of 1000 consecutive patients treated at a single institute. <i>Surgery</i> , 2008, 143, 499-508.	1.0	155
9	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA). <i>Lancet Oncology</i> , 2020, 21, 1620-1629.	5.1	152
10	Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. <i>Cancer</i> , 1997, 74, 459-463.		151
11	Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. <i>International Journal of Clinical Oncology</i> , 2010, 15, 135-144.	1.0	136
12	Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. <i>PLoS Genetics</i> , 2016, 12, e1005778.	1.5	134
13	Sarcopenia is an independent predictor of complications after colorectal cancer surgery. <i>Surgery Today</i> , 2018, 48, 151-157.	0.7	118
14	An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression. <i>Cancer Research</i> , 2015, 75, 4985-4997.	0.4	113
15	CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. <i>International Journal of Colorectal Disease</i> , 2017, 32, 99-106.	1.0	108
16	Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). <i>Gastric Cancer</i> , 2016, 19, 968-976.	2.7	101
17	Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1119-1127.	1.7	100
18	Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1804-1810.	0.7	91

#	ARTICLE	IF	CITATIONS
19	Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. <i>Nucleic Acids Research</i> , 1997, 25, 3415-3420.	6.5	87
20	DNA replication stress and cancer chemotherapy. <i>Cancer Science</i> , 2018, 109, 264-271.	1.7	80
21	Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. <i>Human Pathology</i> , 2015, 46, 1890-1900.	1.1	79
22	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. <i>Cancer Immunology Research</i> , 2016, 4, 520-530.	1.6	79
23	Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. <i>International Journal of Clinical Oncology</i> , 2015, 20, 767-775.	1.0	78
24	Indocyanine Green Fluorescence Angiography for Quantitative Evaluation of Gastric Tube Perfusion in Patients Undergoing Esophagectomy. <i>Journal of the American College of Surgeons</i> , 2015, 221, e37-e42.	0.2	77
25	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. <i>Gastric Cancer</i> , 2017, 20, 175-181.	2.7	77
26	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020, 159, 2146-2162.e33.	0.6	75
27	Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1574.	3.4	74
28	CIRCULATEâ€‘Japan: Circulating tumor DNAâ€‘guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 2915-2920.	1.7	74
29	Realâ€‘world data on microsatellite instability status in various unresectable or metastatic solid tumors. <i>Cancer Science</i> , 2021, 112, 1105-1113.	1.7	73
30	The requirement of Mettl3-promoted <i>MyoD</i> mRNA maintenance in proliferative myoblasts for skeletal muscle differentiation. <i>Open Biology</i> , 2017, 7, 170119.	1.5	71
31	Chemosensitivity and Survival in Gastric Cancer Patients with Microsatellite Instability. <i>Annals of Surgical Oncology</i> , 2009, 16, 2510-2515.	0.7	70
32	Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair. <i>Oncogene</i> , 1999, 18, 2143-2147.	2.6	68
33	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. <i>Genome Medicine</i> , 2016, 8, 136.	3.6	64
34	Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin WithÂ‘Regard to Invasion and Metastasis of BreastÂ‘Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1003-e1009.	1.1	64
35	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 982-986.	2.9	64
36	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641.	0.8	63

#	ARTICLE	IF	CITATIONS
37	12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2906-2913.	0.8	62
38	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	2.7	60
39	Actionable gene-based classification toward precision medicine in gastric cancer. <i>Genome Medicine</i> , 2017, 9, 93.	3.6	59
40	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to Trastuzumab (KSCC1604). <i>European Journal of Cancer</i> , 2018, 105, 41-49.	1.3	58
41	IgG4-related disease of the ileocecal region mimicking malignancy: A case report. <i>International Journal of Surgery Case Reports</i> , 2014, 5, 669-672.	0.2	57
42	Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability. <i>Nucleic Acids Research</i> , 2005, 33, 1628-1636.	6.5	55
43	High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. <i>Cancer Science</i> , 2010, 101, 639-645.	1.7	55
44	Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. <i>Cancer Medicine</i> , 2015, 4, 75-83.	1.3	55
45	Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1004-1013.	1.9	55
46	Clinical significance of programmed cell death ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. <i>International Journal of Cancer</i> , 2018, 142, 822-832.	2.3	55
47	Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1-LBA1.	0.8	52
48	Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. <i>Cell Reports</i> , 2017, 19, 969-980.	2.9	51
49	The triangulating stapling technique for cervical esophagogastric anastomosis after esophagectomy. <i>Surgery Today</i> , 2009, 39, 201-206.	0.7	49
50	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. <i>Annals of Surgical Oncology</i> , 2016, 23, 508-515.	0.7	49
51	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. <i>European Journal of Cancer</i> , 2018, 91, 86-91.	1.3	48
52	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	0.8	45
53	C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 355-363.	1.4	44
54	Mortalin is a prognostic factor of gastric cancer with normal p53 function. <i>Gastric Cancer</i> , 2014, 17, 255-262.	2.7	43

#	ARTICLE	IF	CITATIONS
55	Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 498-504.	1.1	42
56	The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 678-685.	0.7	42
57	Differentiation of early gastric cancer with ulceration and resectable advanced gastric cancer using multiphasic dynamic multidetector CT. <i>European Radiology</i> , 2016, 26, 1330-1337.	2.3	41
58	Laparoscopic Proximal Gastrectomy Maintains Body Weight and Skeletal Muscle Better Than Total Gastrectomy. <i>World Journal of Surgery</i> , 2018, 42, 3270-3276.	0.8	41
59	Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 1042-1048.	1.0	40
60	Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 745-753.	0.7	40
61	p53 Gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: Results in Japan and comparisons with other countries. <i>Cancer Science</i> , 2007, 98, 1152-1156.	1.7	39
62	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	3.2	39
63	The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract. <i>Digestion</i> , 2009, 79, 33-39.	1.2	38
64	The Expression of <i>CCAT2</i> , a Novel Long Noncoding RNA Transcript, and rs6983267 Single-Nucleotide Polymorphism Genotypes in Colorectal Cancers. <i>Oncology</i> , 2017, 92, 48-54.	0.9	38
65	Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). <i>British Journal of Cancer</i> , 2019, 121, 222-229.	2.9	37
66	Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. <i>Oncotarget</i> , 2017, 8, 107666-107677.	0.8	37
67	Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 249-257.	1.1	36
68	Recent advances in treatment for colorectal liver metastasis. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 167-175.	1.2	36
69	Frequency of Microsatellite Instability in Breast Cancer Determined by High-Resolution Fluorescent Microsatellite Analysis. <i>Oncology</i> , 2000, 59, 44-49.	0.9	35
70	Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2340-2346.	0.7	35
71	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 147-155.	1.0	35
72	Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trial. <i>Surgery Today</i> , 2018, 48, 865-874.	0.7	35

#	ARTICLE	IF	CITATIONS
73	Amide proton transfer imaging can predict tumor grade in rectal cancer. <i>Magnetic Resonance Imaging</i> , 2018, 51, 96-103.	1.0	35
74	Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. <i>American Journal of Surgery</i> , 2019, 217, 757-763.	0.9	35
75	Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability. <i>Nature Communications</i> , 2016, 7, 11117.	5.8	34
76	Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 19748-19761.	0.8	34
77	High expression of the Notch ligand Jagged1 is associated with poor prognosis after surgery for colorectal cancer. <i>Cancer Science</i> , 2016, 107, 1705-1716.	1.7	32
78	Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent-induced mitotic arrest. <i>Scientific Reports</i> , 2017, 7, 16762.	1.6	32
79	Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients. <i>Digestion</i> , 2019, 99, 6-13.	1.2	32
80	Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 465-472.	0.7	32
81	Impact of Expression of Vimentin and Axl in Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 520-526.e2.	1.1	31
82	Incidence of Venous Thromboembolism Following Laparoscopic Surgery for Gastrointestinal Cancer: A Single-Center, Prospective Cohort Study. <i>World Journal of Surgery</i> , 2016, 40, 309-314.	0.8	31
83	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. <i>Oncology</i> , 2017, 93, 387-394.	0.9	31
84	Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 151-160.	1.2	30
85	Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1032-1043.	1.7	30
86	Prognostic impact of MutT homolog1 expression on esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 258-266.	1.3	29
87	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	1.5	29
88	Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 140-146.	1.4	28
89	Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 492-498.	0.7	28
90	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). <i>Oncologist</i> , 2020, 25, e1855-e1863.	1.9	28

#	ARTICLE	IF	CITATIONS
91	Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers. <i>Surgery Today</i> , 2014, 44, 454-461.	0.7	27
92	SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 1130-1138.	1.5	27
93	The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2332-2342.	1.9	27
94	Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). <i>International Journal of Clinical Oncology</i> , 2019, 24, 1204-1213.	1.0	27
95	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	3.2	27
96	Genetic mutual relationship between PTEN and p53 in gastric cancer. <i>Cancer Letters</i> , 2005, 227, 33-38.	3.2	26
97	Clinical aspect and molecular mechanism of DNA aneuploidy in gastric cancers. <i>Journal of Gastroenterology</i> , 2012, 47, 351-358.	2.3	26
98	Technical Improvement of Total Pharyngo-Laryngo-Esophagectomy for Esophageal Cancer and Head and Neck Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1671-1677.	0.7	26
99	Carbohydrate antigen 19 is a useful prognostic marker in esophagogastric junction adenocarcinoma. <i>Cancer Medicine</i> , 2015, 4, 1659-1666.	1.3	26
100	Evaluation of techniques to prevent colorectal anastomotic leakage. <i>Journal of Surgical Research</i> , 2015, 194, 450-457.	0.8	26
101	High ubiquitin-specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer. <i>Cancer Medicine</i> , 2017, 6, 1453-1464.	1.3	26
102	Histopathologic diversity of gastric cancers: Relationship between enhancement pattern on dynamic contrast-enhanced CT and histological type. <i>European Journal of Radiology</i> , 2017, 97, 90-95.	1.2	26
103	Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. <i>Oncotarget</i> , 2017, 8, 93567-93579.	0.8	26
104	Comparison of Inflammation-Based Prognostic Scores Associated with the Prognostic Impact of Adenocarcinoma of Esophagogastric Junction and Upper Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2059-2067.	0.7	26
105	Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 814-818.	1.4	25
106	Progression from laparoscopic-assisted to totally laparoscopic distal gastrectomy: comparison of circular stapler (i-DST) and linear stapler (BBT) for intracorporeal anastomosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 325-332.	1.3	25
107	Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?. <i>World Journal of Surgery</i> , 2018, 42, 2894-2901.	0.8	25
108	Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 46-59.	1.2	25

#	ARTICLE	IF	CITATIONS
109	Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. <i>Anticancer Research</i> , 2014, 34, 6397-403.	0.5	25
110	The Impact of Obesity on the Use of a Totally Laparoscopic Distal Gastrectomy in Patients with Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2012, 12, 108.	0.9	24
111	Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 780-789.	2.7	24
112	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 37216-37228.	0.8	24
113	Endoscopic evaluation of clinical colorectal anastomotic leakage. <i>Journal of Surgical Research</i> , 2015, 193, 126-134.	0.8	23
114	Lysine-specific demethylase 1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer. <i>International Journal of Cancer</i> , 2016, 138, 428-439.	2.3	23
115	Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis. <i>Oncology</i> , 2016, 91, 31-40.	0.9	23
116	The antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA. <i>Scientific Reports</i> , 2016, 6, 25286.	1.6	23
117	Blood Flow Assessment with Indocyanine Green Fluorescence Angiography for Pedicled Omental Flap on Cervical Esophagogastric Anastomosis after Esophagectomy. <i>Journal of the American College of Surgeons</i> , 2016, 222, e67-e69.	0.2	23
118	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. <i>Annals of Surgical Oncology</i> , 2018, 25, 1564-1571.	0.7	23
119	Comprehensive molecular profiling broadens treatment options for breast cancer patients. <i>Cancer Medicine</i> , 2021, 10, 529-539.	1.3	23
120	Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. <i>Journal of Gastroenterology</i> , 2021, 56, 547-559.	2.3	23
121	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Scientific Reports</i> , 2018, 8, 1005.	1.6	22
122	CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 6258-6268.	1.3	22
123	Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 4267-4273.	0.7	21
124	Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. <i>Cancer Medicine</i> , 2021, 10, 3129-3138.	1.3	21
125	Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. <i>Annals of Surgical Oncology</i> , 2015, 22, 3659-3665.	0.7	20
126	APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. <i>Medical Oncology</i> , 2016, 33, 26.	1.2	20



#	ARTICLE	IF	CITATIONS
127	Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1318-1326.	1.0	20
128	Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. <i>Surgery Today</i> , 2017, 47, 1060-1071.	0.7	19
129	Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist. <i>Human Pathology</i> , 2019, 88, 27-38.	1.1	19
130	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenging with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 674.	1.1	19
131	Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 2975-2985.	0.7	19
132	Diffuse-type gastric cancer: specific enhancement pattern on multiphase contrast-enhanced computed tomography. <i>Japanese Journal of Radiology</i> , 2017, 35, 289-295.	1.0	18
133	Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2015, 35, 4617-24.	0.5	18
134	Detection of disseminated cancer cells in bone marrow of gastric cancer using real time quantitative reverse transcriptase polymerase chain reaction. <i>Cancer Letters</i> , 2002, 188, 191-198.	3.2	17
135	Preservation of an Aberrant Hepatic Artery Arising from the Left Gastric Artery during Laparoscopic Gastrectomy for Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2011, 212, e25-e27.	0.2	17
136	Surgical Resection for Esophageal Cancer Synchronously or Metachronously Associated with Head and Neck Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2434-2439.	0.7	17
137	Overexpression of <i>CXCR7</i> Is a Novel Prognostic Indicator in Gastric Cancer. <i>Digestive Surgery</i> , 2017, 34, 312-318.	0.6	17
138	Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women. <i>PLoS ONE</i> , 2016, 11, e0168090.	1.1	17
139	Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. <i>Anticancer Research</i> , 2015, 35, 2441-6.	0.5	17
140	Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 199-203.	1.1	16
141	Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. <i>Oncology</i> , 2009, 77, 49-52.	0.9	16
142	Newly Developed Liver-Retracting Method for Laparoscopic Gastric Surgery Using a Silicone Disc: The Î-shape Technique. <i>Journal of the American College of Surgeons</i> , 2013, 216, e43-e46.	0.2	16
143	Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). <i>Annals of Surgical Oncology</i> , 2015, 22, 1067-1074.	0.7	16
144	Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency. <i>American Journal of Surgical Pathology</i> , 2018, 42, 172-182.	2.1	16

#	ARTICLE	IF	CITATIONS
145	Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial. <i>Surgery</i> , 2019, 165, 586-592.	1.0	16
146	Clinical significance of signal regulatory protein alpha (SIRP $\alpha$ ) expression in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2021, 112, 3018-3028.	1.7	16
147	Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). <i>Anticancer Research</i> , 2014, 34, 6655-62.	0.5	16
148	Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. <i>Gastric Cancer</i> , 1999, 2, 46-51.	2.7	15
149	Neoadjuvant Chemotherapy <i>versus</i> Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 6809-6814.	0.5	15
150	A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrett's esophagus: literature and review. <i>Surgical Case Reports</i> , 2018, 4, 45.	0.2	15
151	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e687-e697.	1.0	15
152	Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer. <i>Anticancer Research</i> , 2014, 34, 5421-7.	0.5	15
153	Outcome of esophagojejunostomy during totally laparoscopic total gastrectomy: a single-center retrospective study. <i>Anticancer Research</i> , 2014, 34, 7227-32.	0.5	15
154	Surgical Complications and the Risk Factors of Totally Laparoscopic Distal Gastrectomy. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2011, 21, 146-150.	0.4	14
155	Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction. <i>World Journal of Surgery</i> , 2019, 43, 1068-1075.	0.8	14
156	Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex. <i>Cancer Science</i> , 2020, 111, 1008-1019.	1.7	14
157	Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. <i>Cancer Medicine</i> , 2021, 10, 454-461.	1.3	14
158	Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen species accumulation. <i>Gastric Cancer</i> , 2021, 24, 1089-1099.	2.7	14
159	Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. <i>Anticancer Research</i> , 2015, 35, 401-6.	0.5	14
160	Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. <i>Medical Oncology</i> , 2016, 33, 118.	1.2	13
161	Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1986-1992.	0.7	13
162	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS ( KRAS/NRAS ) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	1.0	13

#	ARTICLE	IF	CITATIONS
163	Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. <i>ESMO Open</i> , 2018, 3, e000411.	2.0	13
164	Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. <i>Scientific Reports</i> , 2019, 9, 7964.	1.6	13
165	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 614-621.	1.0	13
166	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 217-223.	1.1	13
167	Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT. <i>PLoS ONE</i> , 2020, 15, e0241140.	1.1	13
168	Changes in expression levels of <i>ERCC1</i> , <i>DPYD</i> and <i>VEGFA</i> mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. <i>Oncotarget</i> , 2015, 6, 34004-34013.	0.8	13
169	High-resolution fluorescent analysis of microsatellite instability in gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 701-709.	0.8	12
170	Transient Elastography for the Prediction of Oxaliplatin-Associated Liver Injury in Colon Cancer Patients : A Preliminary Analysis. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 82-85.	0.6	12
171	Book-Binding Technique for Billroth I Anastomosis During Totally Laparoscopic Distal Gastrectomy. <i>Journal of the American College of Surgeons</i> , 2014, 219, e69-e73.	0.2	12
172	Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 753-758.	0.9	12
173	Clinical significance of ZNF750 gene expression, a novel tumor suppressor gene, in esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 1795-1801.	0.8	12
174	A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer. <i>Histopathology</i> , 2018, 72, 697-703.	1.6	12
175	Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity. <i>Molecular Cancer Research</i> , 2018, 16, 1483-1490.	1.5	12
176	Efficacy of Novel Multispectral Imaging Device to Determine Anastomosis for Esophagogastrostomy. <i>Journal of Surgical Research</i> , 2019, 242, 11-22.	0.8	12
177	Recent developments in cancer research: Expectations for a new remedy. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 419-426.	1.2	12
178	Cancer-derived cholesterol sulfate is a key mediator to prevent tumor infiltration by effector T cells. <i>International Immunology</i> , 2022, 34, 277-289.	1.8	12
179	Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report. <i>Anticancer Research</i> , 2015, 35, 4037-41.	0.5	12
180	Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3419-3429.	0.8	12

#	ARTICLE	IF	CITATIONS
181	Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1499-1507.	0.7	11
182	Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells. <i>Cancer Medicine</i> , 2013, 2, 447-456.	1.3	11
183	Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2608-2614.	0.7	11
184	Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia. <i>Human Pathology</i> , 2016, 52, 145-152.	1.1	11
185	Exploration of potential prognostic biomarkers in aflibercept plus <sc>FOLFIRI</sc> in Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 3565-3572.	1.7	11
186	Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3554-3554.	0.8	11
187	Intratumoral lymphangiogenesis and prognostic significance of VEGFC expression in gastric cancer. <i>Anticancer Research</i> , 2014, 34, 3911-5.	0.5	11
188	Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. <i>Anticancer Research</i> , 2014, 34, 4207-12.	0.5	11
189	Pure laparoscopic right-sided hepatectomy in the semi-prone position for synchronous colorectal cancer with liver metastases. <i>Asian Journal of Endoscopic Surgery</i> , 2014, 7, 133-137.	0.4	10
190	A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). <i>International Journal of Clinical Oncology</i> , 2016, 21, 335-343.	1.0	10
191	Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Surgery Today</i> , 2016, 46, 261-267.	0.7	10
192	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. <i>Surgical Oncology</i> , 2018, 27, 637-641.	0.8	10
193	DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status. <i>Molecular Cancer Research</i> , 2020, 18, 1354-1366.	1.5	10
194	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. <i>Gastric Cancer</i> , 2022, 25, 180-187.	2.7	10
195	Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. <i>Scientific Reports</i> , 2021, 11, 19178.	1.6	10
196	Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer. <i>World Journal of Gastroenterology</i> , 2009, 15, 2520.	1.4	10
197	Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. <i>Anticancer Research</i> , 2015, 35, 2299-303.	0.5	10
198	Clinical significance of cytokeratin positive cells in bone marrow of gastric cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 995-1000.	1.2	9

#	ARTICLE	IF	CITATIONS
199	Successful treatment of tracheo mediastinal fistula after tracheal injury obtained during esophagectomy using the pectoralis major muscle: a case report. <i>Esophagus</i> , 2008, 5, 41-44.	1.0	9
200	The impact of a high-frequency microsatellite instability phenotype on the tumor location-related genetic differences in colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 133-139.	1.0	9
201	Recent advances in multidisciplinary approach for rectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 641-649.	1.0	9
202	Clinical Significance of Totally Laparoscopic Distal Gastrectomy: A Comparison of Short-term Outcomes Relative to Open and Laparoscopic-assisted Distal Gastrectomy. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2016, 26, 372-376.	0.4	9
203	Primary amelanotic malignant melanoma of the esophagus: a case report. <i>Surgical Case Reports</i> , 2019, 5, 4.	0.2	9
204	CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0228002.	1.1	9
205	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 687.	1.1	9
206	Gastric glomus tumor with a preoperative diagnosis by endoscopic ultrasonography-guided fine needle aspiration: a case report. <i>International Cancer Conference Journal</i> , 2021, 10, 35-40.	0.2	9
207	Histological categorisation of the desmoplastic reaction is a predictor of patient prognosis in oesophageal squamous cell carcinoma. <i>Histopathology</i> , 2021, 79, 219-226.	1.6	9
208	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 37-45.	1.2	9
209	Cancer-associated Fibroblast-derived Spondin-2 Promotes Motility of Gastric Cancer Cells. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 521-529.	1.0	9
210	Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11b <sup>high</sup> /Gr1 <sup>high</sup> myeloid cells. <i>Oncotarget</i> , 2018, 9, 17620-17630.	0.8	9
211	Induction of potentially lethal hypermagnesemia, ischemic colitis, and toxic megacolon by a preoperative mechanical bowel preparation: report of a case. <i>Surgical Case Reports</i> , 2016, 2, 18.	0.2	8
212	Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. <i>Scientific Reports</i> , 2017, 7, 16969.	1.6	8
213	Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. <i>In Vivo</i> , 2018, 32, 1491-1498.	0.6	8
214	Principles and development of collagen-mediated tissue fusion induced by laser irradiation. <i>Scientific Reports</i> , 2019, 9, 9383.	1.6	8
215	The balance of forces generated by kinesins controls spindle polarity and chromosomal heterogeneity in tetraploid cells. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	8
216	A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier. <i>Oncology</i> , 2020, 98, 534-541.	0.9	8

#	ARTICLE	IF	CITATIONS
217	FMS-like tyrosine kinase 3 ( FLT3 ) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	1.7	8
218	Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301). <i>BMC Cancer</i> , 2021, 21, 23.	1.1	8
219	Clinical impact of the triple-layered circular stapler for reducing the anastomotic leakage in rectal cancer surgery: Porcine model and multicenter retrospective cohort analysis. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 256-264.	1.2	8
220	Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2018, 38, 491-499.	0.5	8
221	Conversion to Neuroendocrine Carcinoma from Squamous Cell Carcinoma of the Esophagus After Definitive Chemoradiotherapy. <i>Anticancer Research</i> , 2016, 36, 4045-9.	0.5	8
222	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	1.5	8
223	Impact of the suboptimal communication network environment on telerobotic surgery performance and surgeon fatigue. <i>PLoS ONE</i> , 2022, 17, e0270039.	1.1	8
224	The Use of a Circular Side Stapling Technique in Laparoscopic Low Anterior Resection for Rectal Cancer: Experience of 30 Serial Cases. <i>International Surgery</i> , 2015, 100, 979-983.	0.0	7
225	Loss of Heterozygosity of PTEN (Encoding Phosphate and Tensin Homolog) Associated with Elevated HER2 Expression Is an Adverse Prognostic Indicator in Gastric Cancer. <i>Oncology</i> , 2015, 88, 189-194.	0.9	7
226	Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer. <i>Breast</i> , 2016, 25, 62-68.	0.9	7
227	S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). <i>International Journal of Clinical Oncology</i> , 2016, 21, 705-712.	1.0	7
228	Anal metastasis of rectal cancer adenocarcinoma of squamous cells: a case report and literature review. <i>Surgical Case Reports</i> , 2017, 3, 55.	0.2	7
229	The evolution of surgical treatment for gastrointestinal cancers. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1333-1349.	1.0	7
230	Sarcopenia discriminates poor prognosis in elderly patients following emergency surgery for perforation pancreatitis. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 630-637.	1.2	7
231	RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	7
232	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. <i>Clinical Colorectal Cancer</i> , 2021, 20, e173-e184.	1.0	7
233	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2018, 36, 3523-3523.	0.8	7
234	Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. <i>Oncology Reports</i> , 2006, 15, 849-54.	1.2	7

#	ARTICLE	IF	CITATIONS
235	Suppression of MAL gene expression in gastric cancer correlates with metastasis and mortality. Fukuoka Acta Medica, 2013, 104, 344-9.	0.1	7
236	Intensive Immunofluorescence Staining Methods for Low Expression Protein: Detection of Intestinal Stem Cell Marker LGR5. Acta Histochemica Et Cytochemica, 2015, 48, 159-164.	0.8	6
237	A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). International Journal of Clinical Oncology, 2017, 22, 913-920.	1.0	6
238	Gastric cancer with synchronous and metachronous hepatic metastasis predicted by enhancement pattern on multiphasic contrast-enhanced CT. European Journal of Radiology, 2018, 108, 165-171.	1.2	6
239	Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy. Anticancer Research, 2019, 39, 1411-1415.	0.5	6
240	Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Cancer Chemotherapy and Pharmacology, 2020, 85, 1029-1038.	1.1	6
241	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> ( <i>KRAS/NRAS</i> ) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 85-85.	0.8	6
242	The effects of <i>ARID1A</i> mutations on colorectal cancer and associations with <i>PD-L1</i> expression by stromal cells. Cancer Reports, 2022, 5, e1420.	0.6	6
243	Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer. Surgical Case Reports, 2020, 6, 298.	0.2	6
244	DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Science, 2022, 113, 1531-1534.	1.7	6
245	Assessment of surgical treatment and postoperative nutrition in gastric cancer patients older than 80 years. Anticancer Research, 2015, 35, 511-5.	0.5	6
246	Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701). Oncology, 2013, 84, 233-239.	0.9	5
247	Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with <i>KRAS</i> exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Cancer Chemotherapy and Pharmacology, 2016, 78, 585-593.	1.1	5
248	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	0.9	5
249	Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer. Clinical Breast Cancer, 2018, 18, e643-e650.	1.1	5
250	Energy-less technique with mini-clips for recurrent laryngeal nerve lymph node dissection in prone thoracoscopic esophagectomy for esophageal cancer. American Journal of Surgery, 2018, 216, 1212-1214.	0.9	5
251	BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue. Anticancer Research, 2018, 38, 6099-6106.	0.5	5
252	Changing the Dissectable Layer: Novel Thoracoscopic Esophagectomy Method for Lymphadenectomy along the Left Recurrent Laryngeal Nerve. Journal of the American College of Surgeons, 2020, 230, e1-e6.	0.2	5

#	ARTICLE	IF	CITATIONS
253	Autocrine Leukemia Inhibitory Factor Promotes Esophageal Squamous Cell Carcinoma Progression via Src Family Kinase-Dependent Yes-Associated Protein Activation. <i>Molecular Cancer Research</i> , 2020, 18, 1876-1888.	1.5	5
254	Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3608-3608.	0.8	5
255	REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecanâ€”Biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3510-3510.	0.8	5
256	Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3548-3548.	0.8	5
257	The Clinical Usefulness of the LigaSureâ„¢ Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 2359-2362.	0.5	5
258	Staged operation for synchronous quintuple cancer in the oral cavity, hypopharynx, and esophagus. <i>Esophagus</i> , 2012, 9, 228-233.	1.0	4
259	Simultaneous resection of colorectal cancer and liver metastases in the right lobe using pure laparoscopic surgery. <i>Surgery Today</i> , 2014, 44, 1588-1592.	0.7	4
260	Esophageal cancer associated with bilateral hilar lymphadenopathy caused by sarcoid-like reactions: a report of two cases. <i>Esophagus</i> , 2015, 12, 322-326.	1.0	4
261	Development of fistula between esophagogastric anastomotic site and cartilage portion of trachea after subtotal esophagectomy for cervical esophageal cancer: a case report. <i>Surgical Case Reports</i> , 2016, 2, 107.	0.2	4
262	Real-Time Accurate Identification of Tumor Site Using a Mobile X-Ray Image-Intensifier System During Laparoscopic Gastrectomy. <i>Journal of the American College of Surgeons</i> , 2016, 222, e1-e7.	0.2	4
263	Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 147-153.	1.1	4
264	Recurrence with pagetoid spread arising 17 years after surgery for intramucosal rectal cancer: a case report. <i>Surgical Case Reports</i> , 2017, 3, 85.	0.2	4
265	Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors. <i>Journal of Histochemistry and Cytochemistry</i> , 2018, 66, 549-561.	1.3	4
266	Non-familial juvenile polyposis of the stomach with gastric cancers: a case report. <i>Surgical Case Reports</i> , 2018, 4, 79.	0.2	4
267	Intestinal Behçetâ€™s Disease with Primary Myelofibrosis Involving Trisomy 8. <i>Acta Haematologica</i> , 2019, 142, 253-256.	0.7	4
268	CT gastrography â€œwall-carving techniqueâ€”of gastric cancer: impact of contrast enhancement based on layer depth. <i>Japanese Journal of Radiology</i> , 2019, 37, 597-604.	1.0	4
269	Factors of incomplete colonoscopy for stenosing colorectal cancer: CT colonography features. <i>Japanese Journal of Radiology</i> , 2020, 38, 973-978.	1.0	4
270	Identification of characteristic compounds of moderate volatility in breast cancer cell lines. <i>PLoS ONE</i> , 2020, 15, e0235442.	1.1	4



#	ARTICLE	IF	CITATIONS
271	Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. <i>International Journal of Cancer</i> , 2021, 148, 1260-1275.	2.3	4
272	Mutational signatures in squamous cell carcinoma of the lung. <i>Journal of Thoracic Disease</i> , 2021, 13, 1075-1082.	0.6	4
273	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1459-1463.	0.4	4
274	Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study. <i>Esophagus</i> , 2022, 19, 57-68.	1.0	4
275	Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4038-4038.	0.8	4
276	Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review. , 2017, 37, 5687-5691.		4
277	Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1063-1075.	1.4	4
278	Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01.. <i>Journal of Clinical Oncology</i> , 2022, 40, 168-168.	0.8	4
279	Case of early adenosquamous carcinoma of the stomach. <i>Fukuoka Acta Medica</i> , 2013, 104, 315-20.	0.1	4
280	Significance of stroke volume variation during hepatic resection under infrahepatic inferior vena cava and portal triad clamping. <i>Fukuoka Acta Medica</i> , 2013, 104, 362-9.	0.1	4
281	Laparoscopic Total Gastrectomy for RCC: Four Case Reports. <i>Anticancer Research</i> , 2015, 35, 5023-6.	0.5	4
282	CD44v3,8&#x2013;10 is essential for Slug&#x2013;dependent <i>vimentin</i> gene expression to acquire TGF&#x2013;1&#x2013;induced tumor cell motility. <i>Cancer Science</i> , 2022, 113, 2654-2667.	1.7	4
283	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). <i>International Journal of Clinical Oncology</i> , 2016, 21, 110-117.	1.0	3
284	New Anastomosis Technique to Prevent Anastomotic Leakage in Laparoscopic Anterior Resection for Rectal Cancer, Especially Upper Rectal Cancer. <i>In Vivo</i> , 2020, 34, 3533-3538.	0.6	3
285	Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. <i>International Cancer Conference Journal</i> , 2020, 9, 127-132.	0.2	3
286	Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1115-1122.	1.0	3
287	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.. <i>Journal of Clinical Oncology</i> , 2021, 39, 106-106.	0.8	3
288	Measurement of circumferential tumor extent of colorectal cancer on CT colonography: relation to clinicopathological features and patient prognosis after surgery. <i>Japanese Journal of Radiology</i> , 2021, 39, 966-972.	1.0	3

#	ARTICLE	IF	CITATIONS
289	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. <i>Investigational New Drugs</i> , 2021, 39, 1649-1655.	1.2	3
290	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2025-2028.	1.0	3
291	Significance of the vimentin expression in triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1056-1056.	0.8	3
292	Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3528-3528.	0.8	3
293	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS215-TPS215.	0.8	3
294	Application of splenectomy to decompress portal pressure in left lobe living donor liver transplantation. <i>Fukuoka Acta Medica</i> , 2013, 104, 282-9.	0.1	3
295	Total laparoscopic distal gastrectomy for elderly patients with gastric cancer. <i>Fukuoka Acta Medica</i> , 2013, 104, 290-8.	0.1	3
296	Minimally invasive total pharyng-laryngo-esophagectomy and reconstruction with gastric tube: report of three cases. <i>Fukuoka Acta Medica</i> , 2013, 104, 442-8.	0.1	3
297	Cardiac tamponade due to bleeding as a potential lethal complication after surgery for esophageal cancer. <i>Anticancer Research</i> , 2015, 35, 407-11.	0.5	3
298	Laparoscopic Gastrectomy for Gastric Cancer with Peritoneal Dissemination after Induction Chemotherapy. <i>Case Reports in Gastroenterology</i> , 2013, 7, 516-521.	0.3	2
299	Diagnosis of early colorectal cancer invasion depth by quantitative evaluation of the basal indentation in CT colonography. <i>Japanese Journal of Radiology</i> , 2016, 34, 786-794.	1.0	2
300	Distant lymph node metastases caused by esophageal cancer invasion to the lamina propria: a case report. <i>Surgical Case Reports</i> , 2016, 2, 143.	0.2	2
301	Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan. <i>International Journal of Clinical Oncology</i> , 2017, 22, 505-510.	1.0	2
302	Effect of age factors on health-related quality of life in patients with lower rectal cancer after sphincter-saving surgery: A 1-year longitudinal study. <i>Archives of Gerontology and Geriatrics</i> , 2018, 79, 185-191.	1.4	2
303	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 1116.	1.1	2
304	A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 285-294.	1.1	2
305	Thoracoscopic esophagectomy in total pharyngolaryngoesophagectomy for esophageal cancer; A case series. <i>Annals of Medicine and Surgery</i> , 2020, 60, 9-13.	0.5	2
306	Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model. <i>Laboratory Investigation</i> , 2021, 101, 12-25.	1.7	2

#	ARTICLE	IF	CITATIONS
307	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. <i>Clinical Colorectal Cancer</i> , 2021, 20, e129-e138.	1.0	2
308	Indications for laparoscopic surgery for older rectal cancer patients with comorbidities. <i>Surgery Today</i> , 2021, 51, 721-726.	0.7	2
309	ASO Author Reflection: Radiomics-Based Prediction for the Responder to First-Line Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastasis. <i>Annals of Surgical Oncology</i> , 2021, 28, 2986-2987.	0.7	2
310	Feasibility of hepatic resection for liver metastasis of head-and-neck carcinoma or esophageal carcinoma: a multi-center experience. <i>Surgery Today</i> , 2021, 51, 1932-1937.	0.7	2
311	Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment. <i>Cancer Science</i> , 2021, 112, 2436-2441.	1.7	2
312	Liver resectability following S-1+L-OHP with cetuximab as the first-line treatment of unresectable liver limited metastases from KRAS exon 2 wild-type colorectal cancer in Japanese patients (KSCC 1002). <i>Journal of Clinical Oncology</i> , 2015, 33, 755-755.	0.8	2
313	Differential expression of insulin-like growth factor 1 in human primary liver cancer. <i>Fukuoka Acta Medica</i> , 2013, 104, 334-8.	0.1	2
314	Living donor liver transplantation followed by total gastrectomy--a two-stage planned operative strategy for early gastric cancer concomitant with decompensated liver cirrhosis. <i>Anticancer Research</i> , 2014, 34, 4307-10.	0.5	2
315	One-stage Procedure for Concomitant Abdominal Aortic Aneurysm and Gastric Cancer. <i>Anticancer Research</i> , 2015, 35, 6909-12.	0.5	2
316	Three-dimensional imaging of intramural perineural invasion in colorectal cancer: Three-dimensional reconstruction approach with multiple immunohistochemically stained sections. <i>Pathology International</i> , 2022, 72, 293-299.	0.6	2
317	A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701. <i>European Journal of Cancer</i> , 2022, 166, 279-286.	1.3	2
318	Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. <i>BMC Cancer</i> , 2021, 21, 1332.	1.1	2
319	The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. <i>Cancer Science</i> , 2021, , .	1.7	2
320	Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer. <i>International Cancer Conference Journal</i> , 2015, 4, 151-154.	0.2	1
321	Mixed spindle and epithelioid cell type gastrointestinal stromal tumor of the esophagus: a case report. <i>Esophagus</i> , 2016, 13, 301-305.	1.0	1
322	Successful surgical intervention for rectal perforation due to polyarteritis nodosa: report of a case. <i>Surgical Case Reports</i> , 2017, 3, 43.	0.2	1
323	Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin+S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. <i>BMC Cancer</i> , 2018, 18, 57.	1.1	1
324	Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report. <i>Surgical Case Reports</i> , 2019, 5, 72.	0.2	1

#	ARTICLE	IF	CITATIONS
325	Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature. <i>International Cancer Conference Journal</i> , 2020, 9, 116-122.	0.2	1
326	Quadruple gastrointestinal cancer with discordance of mismatch repair protein deficiency and microsatellite instability suggesting Lynch syndrome. <i>International Cancer Conference Journal</i> , 2021, 10, 2-5.	0.2	1
327	Safety and efficacy of S-1 plus oxaliplatin 130Âmg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A). <i>International Journal of Clinical Oncology</i> , 2021, 26, 345-354.	1.0	1
328	Late recurrence of cancer stem cell-positive colorectal cancer liver metastases after 15Âyears. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 613-616.	0.4	1
329	Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. , 1997, 74, 459.		1
330	A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3515-3515.	0.8	1
331	A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3526-3526.	0.8	1
332	Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603.. <i>Journal of Clinical Oncology</i> , 2019, 37, 509-509.	0.8	1
333	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. <i>Journal of Clinical Oncology</i> , 2019, 37, 578-578.	0.8	1
334	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 624-624.	0.8	1
335	Significance of multimodality therapy for esophageal cancer synchronously or metachronously associated with head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 132-132.	0.8	1
336	Two Cases of Advanced Gastric Cancer Showing Multiple Liver Metastases Diagnosed with Paraneoplastic Syndrome. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2014, 39, 900-905.	0.0	1
337	A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report. <i>Anticancer Research</i> , 2017, 37, 1917-1921.	0.5	1
338	The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity. <i>Anticancer Research</i> , 2017, 37, 5249-5254.	0.5	1
339	Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection. <i>Anticancer Research</i> , 2018, 38, 2335-2338.	0.5	1
340	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3560-3560.	0.8	1
341	Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 87-87.	0.8	1
342	Geriatric-8 (G8) screening tool stratified the efficacy of S-1 plus ramucirumab in elderly patients with advanced/recurrent gastric cancer: A post-hoc analysis of the KSCC1701 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 256-256.	0.8	1

#	ARTICLE	IF	CITATIONS
343	Plasma-informed minimal residual disease (MRD) assay: A multicenter prospective study in Japanese patients with stage II colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-161.	0.8	1
344	Verification of our therapeutic criterion for acute cholecystitis: "perform a subemergency laparoscopic cholecystectomy when a patient is judged to be able to tolerate general anesthesia"--the experience in a single community hospital. <i>Fukuoka Acta Medica</i> , 2013, 104, 339-43.	0.1	1
345	Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report. <i>Fukuoka Acta Medica</i> , 2013, 104, 383-8.	0.1	1
346	Thoracoscopic pericardial drainage for gastric tube ulcer penetrated into the pericardium. <i>Fukuoka Acta Medica</i> , 2013, 104, 389-93.	0.1	1
347	Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer. <i>Anticancer Research</i> , 2015, 35, 6207-11.	0.5	1
348	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 126-136.	0.6	1
349	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. <i>Targeted Oncology</i> , 2022, , 1.	1.7	1
350	Preoperative insertion of transanal ileus tubes for treatment of acute obstruction in cancer of the colon and rectum. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2005, 1, 88-91.	0.7	0
351	Histological and biological characteristics of esophageal dysplasia. <i>Esophagus</i> , 2005, 2, 129-132.	1.0	0
352	Huge Gastric Carcinoma Showing an Exophytic Growth Pattern: A Case Report and Review of the Literature. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 42-45.	0.6	0
353	Pharyngo-laryngo-esophagectomy and reconstruction with a gastric tube for corrosive pharyngoesophagitis. <i>Esophagus</i> , 2015, 12, 360-364.	1.0	0
354	Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1397-1405.	1.0	0
355	Obstructive rectal endometriosis treated by robot-assisted laparoscopic surgery: a case report. <i>Surgical Case Reports</i> , 2020, 6, 211.	0.2	0
356	A rare case of esophageal adenocarcinoma with urinary bladder metastasis. <i>International Cancer Conference Journal</i> , 2020, 9, 231-234.	0.2	0
357	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). <i>Oncology</i> , 2020, 98, 719-726.	0.9	0
358	A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4043-4043.	0.8	0
359	Pre-treatment status of inflammation-based biomarkers in the patients with advanced gastric cancer who will be treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16107-e16107.	0.8	0
360	Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3558-3558.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Comparison of efficacy between irinotecan and paclitaxel monotherapy as second- or third-line chemotherapy after S-1 containing regimen for advanced or recurrent gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14722-e14722.	0.8	0
362	Prognostic significance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e14033-e14033.	0.8	0
363	Neoadjuvant chemoradiotherapy for potentially resectable esophageal squamous cell carcinoma and the significance of Rad51 expression as a factor predictive of the treatment response.. Journal of Clinical Oncology, 2012, 30, e14601-e14601.	0.8	0
364	Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 106-106.	0.8	0
365	A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902).. Journal of Clinical Oncology, 2013, 31, 583-583.	0.8	0
366	Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 74-74.	0.8	0
367	S-1/docetaxel compared with the other standard S-1 based regimens as a first-line chemotherapy for patients with advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15173-e15173.	0.8	0
368	A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802).. Journal of Clinical Oncology, 2013, 31, e14633-e14633.	0.8	0
369	TP53 mutation and BUBR1 overexpression characterize the DNA aneuploidy of gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15039-e15039.	0.8	0
370	A Case of Curatively Resected Rectal Cancer with Liver Metastasis and Bladder Invasion Responding to IRIS+Camab. Nihon Gekakei Rengo Gakkaiishi (Journal of Japanese College of Surgeons), 2014, 39, 734-738.	0.0	0
371	Changes in expression levels of excision repair cross-complementing group 1 (ERCC1) and dihydropyrimidine dehydrogenase (DPD) after first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer: Results of a multicenter study.. Journal of Clinical Oncology, 2014, 32, 463-463.	0.8	0
372	Relationship of global DNA hypomethylation-mediated chromosomal instability to the initiation and progression of esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15011-e15011.	0.8	0
373	Trastuzumab plus chemotherapy based on the accurate HER2-positivity testing for patients with advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, e15075-e15075.	0.8	0
374	HER2 and programmed death-1 ligand-1 (PD-L1) expression in gastric carcinoma.. Journal of Clinical Oncology, 2014, 32, e15041-e15041.	0.8	0
375	Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).. Journal of Clinical Oncology, 2014, 32, TPS3662-TPS3662.	0.8	0
376	Aberrations of BUBR1 expression and TP53 gene in human colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14578-e14578.	0.8	0
377	Rapidly Increased Peritoneal Metastases of Squamous Cell Carcinoma of the Upper Thoracic Esophagus after Preoperative Chemoradiotherapy—A Case Report—; Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2015, 76, 2706-2711.	0.0	0
378	A prospective study of XELIRI plus bevacizumab as the first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).. Journal of Clinical Oncology, 2015, 33, 752-752.	0.8	0

#	ARTICLE	IF	CITATIONS
379	A prospective study of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).. Journal of Clinical Oncology, 2015, 33, 129-129.	0.8	0
380	Validation of postoperative adjuvant chemotherapy for elderly patients with stage II/III gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15036-e15036.	0.8	0
381	A central review of liver resectability and pathological tumor response after chemotherapy in patients with initially unresectable colorectal cancer liver metastases: Phase II trials of mFOLFOX6 plus bevacizumab (KSCC0802), and SOX (S-1 and oxaliplatin) plus cetuximab (KSCC1002).. Journal of Clinical Oncology, 2015, 33, e14548-e14548.	0.8	0
382	Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus. Thermal Medicine, 2017, 33, 63-73.	0.0	0
383	The clinical impact of the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score on breast cancer patients survival.. Journal of Clinical Oncology, 2017, 35, 1560-1560.	0.8	0
384	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. Journal of Clinical Oncology, 2018, 36, 10094-10094.	0.8	0
385	MSI-low is an intermediate type between MSI-high and MSS in esophagogastric junction adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 44-44.	0.8	0
386	Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world.. Journal of Clinical Oncology, 2019, 37, e14074-e14074.	0.8	0
387	Efficacy and safety of neoadjuvant chemotherapy for locally advanced gastric cancer in elderly patients: A phase II trial (KSCC1801).. Journal of Clinical Oncology, 2022, 40, 254-254.	0.8	0
388	Rendezvous technique treatment for late-onset biliary leakage after major hepatectomy of a living donor: report of a case. Fukuoka Acta Medica, 2013, 104, 309-14.	0.1	0
389	Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation. Fukuoka Acta Medica, 2013, 104, 376-82.	0.1	0
390	Laparoscopic Resection of Gastric Cancer in a Patient with Chronic Lymphocytic Leukemia Accompanied by Neutropenia. Anticancer Research, 2016, 36, 1779-83.	0.5	0
391	Influence of Robotic Rectal Resection Versus Laparoscopic Rectal Resection on Postoperative Ileus: A Single-center Experience. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2022, Publish Ahead of Print, .	0.4	0
392	Title is missing!. , 2020, 15, e0228002.		0
393	Title is missing!. , 2020, 15, e0228002.		0
394	Title is missing!. , 2020, 15, e0228002.		0
395	Title is missing!. , 2020, 15, e0228002.		0
396	Title is missing!. , 2020, 15, e0228002.		0

#	ARTICLE	IF	CITATIONS
397	Title is missing!. , 2020, 15, e0228002.		0
398	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.. Journal of Clinical Oncology, 2022, 40, 4086-4086.	0.8	0
399	VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.. Journal of Clinical Oncology, 2022, 40, 4028-4028.	0.8	0